Edwards Lifesciences Corp (EW)vsNeogen Corporation (NEOG)
EW
Edwards Lifesciences Corp
$82.67
+1.20%
HEALTHCARE · Cap: $48.01B
NEOG
Neogen Corporation
$9.16
+0.55%
HEALTHCARE · Cap: $1.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 589% more annual revenue ($6.07B vs $880.32M). EW leads profitability with a 17.7% profit margin vs -68.5%. NEOG appears more attractively valued with a PEG of 0.66. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
NEOG
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-544.4%
Fair Value
$12.31
Current Price
$82.67
$70.36 premium
Intrinsic value data unavailable for NEOG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 23.7%
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 76.6%
Smaller company, higher risk/reward
Weak financial health signals
ROE of -25.3% — below average capital efficiency
Revenue declined 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.
Bull Case : NEOG
The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.7x leaves little room for execution misses.
Bear Case : NEOG
The primary concerns for NEOG are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
EW profiles as a mature stock while NEOG is a turnaround play — different risk/reward profiles.
NEOG carries more volatility with a beta of 1.95 — expect wider price swings.
EW is growing revenue faster at 13.3% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 41/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Neogen Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?